Streetbeat News

Regulatory

SPY

Chicago Fed President Goolsbee stated in an FT interview that the recent fall in US inflation is not just a temporary occurrence. He also mentioned that housing costs are a 'negative surprise' but the overall trend for prices is still downward.

Portfolio Pulse from Charles Gross

October 16, 2023 | 10:07 am

IRWD

Ironwood Pharmaceuticals presented final data from its Phase 2 STARS Nutrition Program during United European Gastroenterology Week. The data evaluated Apraglutide for Short Bowel Syndrome with Intestinal Failure and Colon-in-continuity, showing a 50% reduction of parenteral support (PS) volume, 100% of patients were clinical responders, and 78% of patients achieved one or more days off PS.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 10:05 am

ESTA

The FDA has granted 510(k) clearance to Establishment Labs for its Motiva Flora SmoothSilk Tissue Expander. This makes Flora the only magnet-free and MR Conditional tissue expander cleared for the U.S. market.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 10:03 am

VGK

The Eurozone trade balance for August was reported at 6.7 billion, slightly higher than the prior figure of 6.5 billion.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 9:00 am

AZN

AstraZeneca's supplemental New Drug Application (sNDA) for Tagrisso in combination with chemotherapy has been granted Priority Review by the FDA for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer. The FDA's decision is expected in the first quarter of 2024.

Portfolio Pulse from Charles Gross

October 16, 2023 | 8:44 am

GILD

Gilead Sciences is set to participate in the 19th European AIDS Conference in Warsaw, Poland from October 18-21, 2023. The company will provide updates on its signature initiatives, key collaborations, and new scientific data from its HIV research and development programs. The focus will be on the long-term and real-world HIV research, particularly on the treatment with Biktarvy® and Sunlenca®.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:45 am

MRUS

Merus has published two abstracts on the European Society for Medical Oncology Congress (ESMO) 2023 website, highlighting updated interim clinical data from the ongoing phase 1/2 eNRGy trial and Early Access Program (EAP) of the bispecific antibody zenocutuzumab in patients with neuregulin 1 fusion cancer. The ESMO Congress 2023 will take place in Madrid, Spain October 20-24, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:32 am

BNR

Burning Rock has received a breakthrough device designation from China's NMPA for its multi-cancer early detection test. This designation could potentially expedite the development and review process of the test.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:24 am

ARVN

Arvinas is set to present updated Phase 1/2 trial data for Bavdegalutamide (ARV-110) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 7:17 am